Blade Air Mobility, INC 8-K filings

Strata Critical Medical announced a 60.7% year-over-year revenue increase to $72.5 million in Q2 2026, driven by acquisitions and organic growth, alongside improved Adjusted EBITDA and positive operating cash flow.

Strata Critical Medical, Inc. announced the results of its annual meeting of stockholders, including the election of directors and ratification of its independent auditor.

Strata Critical Medical announced first quarter 2026 financial results, showcasing significant year-over-year revenue growth and improved profitability, alongside strategic acquisitions and reiterated full-year guidance.

Strata Critical Medical announced strong fourth quarter 2025 results with an 83.5% year-over-year revenue increase and raised its full year 2026 financial guidance.

Strata Critical Medical, Inc. has closed a $30 million asset-based revolving credit facility, expandable to $50 million, to fund its acquisition strategy while keeping its aircraft fleet unencumbered.

Strata Critical Medical, a leader in organ transplant logistics, expanded its board and appointed healthcare veteran Will Cook as an independent director.

Strata Critical Medical filed audited Keystone results and pro forma statements reflecting the Keystone acquisition and the sale of its Passenger business to Joby Aviation’s subsidiary, detailing consideration, contingencies, and combined performance.

Strata Critical Medical reported a 36.7% year-over-year revenue increase to $49.3 million in Q3 2025, driven by strategic acquisitions and organic growth, leading to raised full-year revenue guidance.

Strata Critical Medical, Inc. has completed the acquisition of Keystone Perfusion Services, LLC for $124 million, creating an integrated organ recovery platform and diversifying into other critical medical services.

Strata Critical Medical, Inc. announced its decision to hold advisory votes on executive compensation annually, aligning with stockholder preference.

Strata Critical Medical, formerly Blade Air Mobility, has completed the sale of its Passenger business to Joby Aero, Inc. and rebranded to focus entirely on medical logistics.

Strata Critical Medical, Inc. has amended its executive compensation, increasing Co-CEO base salaries and introducing substantial performance-based equity awards linked to financial targets and Total Shareholder Return.

Blade Air Mobility announced the sale of its Passenger division to Joby Aviation for up to $125 million, with the remaining Medical division to rebrand as Strata Critical Medical, Inc., alongside strong Q2 2025 financial performance.

Blade Air Mobility announced the sale of its passenger division to Joby Aviation for up to $125 million, pivoting to a pure-play medical services and logistics business under the new brand Strata Critical Medical.

Blade Air Mobility announces improved Q1 2025 financial results with a reduced net loss and increased revenue, reaffirming its full-year guidance.

Blade Air Mobility held its annual meeting on May 6, 2025, where stockholders elected directors, ratified the appointment of Deloitte & Touche LLP as the company's auditor, and approved advisory votes on executive compensation.

Blade Air Mobility reports improved full-year net loss and Adjusted EBITDA, driven by growth in the Medical and Passenger segments, and reaffirms guidance for double-digit millions of Adjusted EBITDA in 2025.

Blade Air Mobility reports a significant increase in operating cash flow and achieves trailing twelve-month profitability in its Passenger segment, exceeding previous guidance.

Blade Air Mobility reports its first positive Adjusted EBITDA for the second quarter as a public company, driven by strong growth in both its Medical and Passenger segments.

Blade Air Mobility held its annual stockholder meeting on May 2, 2024, where directors were elected and the appointment of an independent auditor was ratified.

Blade Air Mobility reported record-high medical revenue and improved profitability in the first quarter of 2024, driven by strong growth in its medical transport business.

Blade Air Mobility has dismissed Marcum LLP as its independent auditor and appointed Deloitte & Touche LLP, effective for the fiscal year ending December 31, 2024.

Blade Air Mobility has authorized a $20 million share repurchase program, citing expected profitability and a strong balance sheet.

Blade Air Mobility announced a 24.5% increase in Q4 2023 revenue and provided guidance for positive adjusted EBITDA in 2024.